Thermo Fisher Scientific, GSK, Haleon, and Gilead Sciences Sign Multi-Buyer PPA with X-ELIO

Pharmaceutical and Healthcare Companies Secure 245 GWh of Renewable Energy Under Schneider Electric’s Energize Program

Overview

A consortium of pharmaceutical and healthcare companies, led by Thermo Fisher Scientific, has signed a multi-buyer virtual power purchase agreement (VPPA) with Spanish renewable energy developer X-ELIO.

The agreement, executed under the Energize program, involves GSK, Haleon, and Gilead Sciences, with Schneider Electric advising on the transaction. The deal will secure 245 GWh of renewable electricity annually for the next decade from X-ELIO’s Lorca Solar Project in Spain, contributing to the decarbonization of supply chains in the pharmaceutical and healthcare industries.

Thermo Fisher Scientific played a central role in negotiations, leveraging its expertise in sustainable energy procurement to guide the cohort. GSK’s Chief Procurement Officer, Lisa Martin, emphasized that the initiative aligns with the company’s broader commitment to energy security and cost predictability, while Haleon’s Vice President of Sustainability, Sarah McDonald, underscored the importance of collaborative action in achieving corporate net-zero targets.

Gilead Sciences’ Senior Vice President of Corporate Operations, Joydeep Ganguly, framed the deal as a long-term investment in sustainable infrastructure, reinforcing the company’s ambition to transition to 100 percent renewable energy by 2025.

On the generation side, X-ELIO, a Madrid-based solar developer, will supply power from its 369 MW Lorca Solar Project, expected to become operational by early 2026. The company’s Chief Commercial Officer, Mirko Molinari, described the VPPA as a milestone in delivering customized net-zero solutions to corporate buyers.

Schneider Electric’s Sustainability Business, which managed the PPA procurement process, sees the agreement as a blueprint for tackling Scope 3 emissions—the most challenging component of corporate decarbonization efforts.

The deal marks the second multi-buyer PPA executed under the Energize initiative, a program endorsed by the Pharmaceutical Supply Chain Initiative (PSCI) and supported by 24 major pharmaceutical and healthcare firms, including AstraZeneca, Merck, Pfizer, and Sanofi.

With the supply chain accounting for more than half of the sector’s total emissions, the agreement signals growing momentum for collaborative clean energy procurement as companies seek to mitigate climate-related risks and stabilize long-term energy costs.

Offtakers:

• Haleon

  • Name: Haleon

  • Website: https://www.haleon.com

• • Profile: A global leader in consumer health, focused on delivering better everyday health with humanity.

  • Location: Headquartered in Weybridge, United Kingdom.

  • Industry: Pharmaceuticals and Healthcare

  • Sub-industry: Consumer Healthcare

  • Executives Involved: Sarah McDonald, VP of Sustainability

• GSK

  • Name: GSK plc